Which papers cover the rat bones?
Three papers, three measurements. None tested whether ipamorelin prevents fractures in people.
The lengthwise-growth paper found faster bone growth in female rats without a change in total blood IGF-1, a growth-related signal. The mineral-content paper found more mineral as female rats’ bones grew larger, while density in the outer bone tissue stayed unchanged.
The steroid-exposure paper found partial protection of bone formation in female rats given methylprednisolone. This is why bones appear in the ipamorelin discussion. It still leaves treatment for fragile bones in people unproven; the bone page keeps those limits beside each result.
Which papers cover hormone release and meals?
The early animal work and the human studies have different jobs. The species is part of the finding.
The original selectivity paper reports experiments in pigs, rats and rat cells. The pig findings show a growth-hormone response without a similar ACTH or cortisol rise. Those are stress-response hormones. This is animal background, rather than a human safety trial.
The healthy-men infusion study measured drug levels and growth-hormone response. The bowel-surgery trial tested time to a tolerated meal and missed its main goal. The research page explains why a hormone response and a demonstrated health benefit are different things.
The PubMed commentary on sermorelin concerns a different peptide. A source about sermorelin cannot stand in for an ipamorelin trial.
Where are the FDA records?
The safety page describes ingredient status. The detailed review explains the concerns behind the caution.
FDA’s safety tables keep ipamorelin acetate in 503B Category 2, the significant-safety-risk group for larger compounders. It also appears among withdrawn pharmacy nominations. CJC-1295 has a withdrawn entry too; withdrawal isn’t clearance.
FDA’s detailed ipamorelin review discusses the human findings and safety gaps. Its explanation of compounded-drug risks spells out why FDA approval doesn’t cover compounded medicines. A prescription doesn’t change that. The access page explains the terms in everyday language.
Publication details
- The original hormone-selectivity experiments Raun and colleagues · European Journal of Endocrinology · 1998
- Longitudinal bone growth in rats Johansen and colleagues · Growth Hormone & IGF Research · 1999
- Bone mineral content in female rats Svensson and colleagues · Journal of Endocrinology · 2000
- Bone formation in steroid-exposed rats Andersen and colleagues · Growth Hormone & IGF Research · 2001
- Human exposure and hormone-response measurements Gobburu and colleagues · Pharmaceutical Research · 1999
- The controlled trial after bowel resection Beck and colleagues · International Journal of Colorectal Disease · 2014
- FDA’s bulk-substance safety concerns and category tables U.S. Food and Drug Administration · content current as of April 22, 2026
- FDA’s detailed review of ipamorelin and its acetate salt U.S. Food and Drug Administration · October 2024 committee materials
- What FDA approval does not cover in compounded medicines U.S. Food and Drug Administration · Understanding the Risks of Compounded Drugs
- The final 503A bulk-ingredient list Code of Federal Regulations · 21 CFR 216.23 · reproduced by Cornell Law School
- The final 503B bulk-ingredient list U.S. Food and Drug Administration · 503B Bulk Drug Substances List
- A commentary about sermorelin, a different peptide Walker · Clinical Interventions in Aging · 2006